Description

LGD-4033 + MK-677 Stack – Product Information

The combination of LGD-4033 (Ligandrol) and MK-677 (Ibutamoren) is a research stack known for its potential to promote muscle growth and enhance recovery in research subjects.

LGD-4033 is a selective androgen receptor modulator (SARM) that selectively binds to androgen receptors in muscle and bone tissues. By binding to these receptors, LGD-4033 may stimulate anabolic effects, potentially leading to increased protein synthesis, muscle growth, and improved muscle strength.

MK-677 is a growth hormone secretagogue that works by stimulating the release of growth hormone and increasing levels of insulin-like growth factor 1 (IGF-1). This increase in growth hormone and IGF-1 levels may contribute to enhanced muscle growth, improved recovery, and potential benefits for bone density and sleep quality.

When studied together, LGD-4033 and MK-677 may have a synergistic effect on muscle growth and recovery. LGD-4033’s selective binding to androgen receptors may enhance protein synthesis and muscle development, while MK-677’s ability to increase growth hormone levels may further support muscle growth and recovery processes.

The combination of LGD-4033 and MK-677 has been explored in preclinical and research studies to better understand their potential synergistic effects on muscle mass and performance.

• LGD-4033 + MK-677 Stack consists of 10mg LGD-4033 and 10mg MK-677.
• Tablets are offered in 2 variants: 20mg per tablet for 27 tablets, totaling 540mg, and 20mg per tablet for 54 tablets, totaling 1080mg.
• Capsules are offered as 20mg per capsule for 60 capsules, totaling 1200mg.

LGD-4033 (Ligandrol)

Ligandrol (LGD-4033) is a novel nonsteroidal oral selective androgen receptor modulator currently being investigated in research as a potential treatment for conditions relating to muscle dystrophy and osteoporosis.

Recent studies investigated the effects of LGD 4033 on muscle tissue in ovariectomized rats. A daily dose of LGD was administered and calculated according to the body weight of each individual rat at the onset of the study. Results and changes were noted as soon as week 2, the control group having weighed significantly less than rats undergoing LGD treatment. This difference remained until the end of the study, irrespective of LGD treatments. Additionally, the LGD treatments resulted in a higher number of capillaries in all muscles studied. Longer randomized trials and research could potentially evaluate its efficacy in improving physical function and health outcomes in select populations.

MK-677 (Ibutamoren)

A recent study set out to investigate the effects of Ibutamoren (MK-677) as a Ghrelin mimetic on body composition and clinical outcomes in healthy older adults. It was found that MK-677 enhanced fluctuating growth hormone secretion and markedly increased fat-free mass over a 12-month period. More extensive research and randomized trials could potentially evaluate its efficacy in improving physical function and health outcomes in select populations.